What's in a Drug Name? Part II: Gene Therapy
- John Q Leonard
- Jan 8, 2024
- 4 min read
Part II: Decoding the Language of Gene Therapy
In the first article of this series, we explored how the names of medicines often reveal far more than most people realize. Once you understand the language of pharmacology, a generic drug name becomes more than a scientific label. It becomes a concise description of biology, mechanism, and therapeutic intent.
Nowhere is that more evident than in gene therapy.
Unlike traditional small molecules or even monoclonal antibodies, gene therapies are extraordinarily complex. Every product consists of multiple engineered components working together, each carrying important scientific and clinical implications.
As gene therapies move from rare diseases into larger therapeutic areas, understanding their nomenclature becomes increasingly valuable for scientists, clinicians, investors, business development professionals, and anyone navigating modern biotechnology.
Why Gene Therapy Required an Entirely New Naming System
Traditional pharmaceuticals generally describe a single active molecule.
Gene therapies are fundamentally different.
Each therapy combines several independent technologies into a single medicinal product.
The therapeutic gene.
The delivery vehicle.
The biological mechanism.
The intended target.
The regulatory authorities responsible for International Nonproprietary Names (INN) recognized that these products required an entirely new approach to nomenclature.
Rather than assigning a simple generic name, gene therapies communicate information about both the therapeutic payload and the vector responsible for delivering it.
In many respects, the name itself becomes a compact engineering diagram.
The Gene Component
The first word in a gene therapy name generally describes the therapeutic genetic payload.
Like traditional medicines, every product begins with a unique fantasy prefix that distinguishes one therapy from another.
The middle portion often provides clues regarding the biological function of the inserted gene.
Examples include therapies involving:
Growth factors
Coagulation factors
Interleukins
Tumor suppressor genes
Retinal proteins
Lipoproteins
Immune modulators
Survival motor neuron (SMN) genes
The suffix -gene identifies the therapeutic component itself.
Even before reading a clinical publication, an experienced scientist can often recognize the broad biological strategy being employed.
The Delivery Vehicle Matters Just as Much
Delivering genetic material safely into human cells remains one of gene therapy's greatest engineering challenges.
For that reason, the second portion of the generic name identifies the vector responsible for transporting the therapeutic gene.
Common examples include vectors based on:
Adeno-associated virus (AAV)
Lentivirus
Adenovirus
Herpes simplex virus
Retrovirus
Vaccinia virus
Plasmid DNA
Each vector possesses unique biological characteristics.
Different tissue tropisms.
Different payload capacities.
Different persistence profiles.
Different immunogenicity.
Different manufacturing considerations.
These distinctions influence not only efficacy, but also safety, manufacturing, regulatory strategy, and commercial development.
The nomenclature reflects that importance.
Why This Matters Beyond Scientists
At first glance, these naming conventions may appear relevant only to molecular biologists.
In reality, they provide valuable context across the biotechnology industry.
Business development professionals quickly recognize competing platforms.
Investors identify technology trends.
Commercial teams understand emerging therapeutic modalities.
Regulatory professionals appreciate the underlying biology.
Even physicians benefit from understanding how delivery systems differ between products.
As advanced therapeutics become increasingly common, fluency in this scientific language becomes an important competitive advantage.
Gene Therapy Reflects a Larger Shift in Medicine
Perhaps the most interesting aspect of gene therapy nomenclature is what it reveals about the evolution of medicine itself.
Historically, drug names primarily described chemistry.
Today's advanced therapeutics increasingly describe engineered biological systems.
The distinction is profound.
Modern medicines are no longer simply molecules interacting with receptors.
They are programmable biological platforms.
Genes.
Vectors.
Engineered cells.
Messenger RNA.
Genome editing systems.
Synthetic biology.
The language of medicine is evolving because medicine itself is evolving.
Looking Ahead
Gene therapy represents only one chapter in the rapidly expanding vocabulary of advanced therapeutics.
Messenger RNA medicines.
Cell therapies.
Antibody-drug conjugates.
Bispecific antibodies.
RNA interference.
Genome editing technologies.
Each has introduced new naming conventions that reflect increasingly sophisticated biological engineering.
Understanding those conventions is more than an academic exercise.
It offers insight into where biotechnology is headed.
Sometimes a medicine's name simply identifies the product.
Increasingly, it tells the story of the platform that made it possible.
In the next installment of this series, we'll explore another rapidly evolving area of biotechnology nomenclature and what those names reveal about the future of drug discovery.
A rose by any other name
Gene Therapy Drugs Elements of Name Elements and Examples
Three elements have been identified that are important in distinguishing a gene therapy drug and conveying safety information to the user physician. These are:
Indication of the drug’s mechanism of action or pharmacologic class. [Note that administration of these gene therapy products frequently results in expression of a biologically active protein];
The vector used in transfection; and
Complete identification of the genes carried by the vector if there are 1 or 2 transgenes; for vectors containing >3 transgenes, 1 or 2 genes will be chosen to be included in the gene qualifier based on an analysis of the impact that they have on preventing product confusion or conveying safety information.
Additional nomenclature elements would be a fantasy syllable(s) that serves as a unique identifier for the molecular entity and a stem indicating the gene therapy class of products or the ability of the vector to replicate. Based on these elements, the following is proposed:
First Word: Corresponds to the Gene Component
Prefix: Fantasy element to provide unique identification; to contribute to the distinct name.
Infix: Element to denote the gene’s mechanism of action (pharmacologic class) such as:
-ald- [adrenoleukodystrophy (ALD) protein]
-beglo- [βA-t87Q-globin]
-bermin- [vascular endothelial growth factor]
-cabta- [cell expressed antibody and T cell activation]
-cima- [cytosine deaminase]
-ermin- [growth factor]
-etid- [eczema-throbocytopenia-immunodeficiency syndrome]
-far- [interferon]
-fermin- [fibroblast growth factor]
-kin- [interleukins]
-lim- [immunomodulator]
-lip- [human lipoprotein lipase]
-mul- [multiple gene]
-naco- [coagulation factor IX]
-nad- [NADH dehydrogenase]
-nermin- [tumor necrosis factor (TNF)]
-octoco- [coagulation factor Vlll]
-pap- [human papilloma virus]
-papkino- [human papilloma virus and IL-2]
-permin- [hepatocyte growth factor]
-repi- [REP-1 gene]
-reti- [retinal pigment]
-semn- [SMN]
-stim- [colony stimulating factor]
-tima- [thymidine kinase]
-tusu- [tumor suppression]
Stem: Element to indicate gene.
-gene
Second Word: Corresponds to the Vector Component
Prefix: Fantasy element to provide unique identification; to contribute to the distinct name
Infix: Element to denote the type of viral vector such as:
-adeno- [adenovirus]
-cana- [canarypox virus]
-foli- [fowlpox virus]
-herpa- [herpes virus]
-lenti- [lentivirus]
-morbilli- [paramyxoviridae morbillivirus]
-parvo- [adeno-associated virus (parvovirdae dependovirus)]
-retro- [other retro viruses]
-vaci- [vaccinia virus]
Stem: Element to identify type of vector
-vec [non-replicating viral vector]
-repvec [replicating viral vector]
-plasmid [plasmid vector]
Comments